Defactinib hydrochloride

盐酸地法替尼

Report date: 2026/03/11 20:02:12
NME

Base Information

Drug NameDefactinib hydrochloride
Drug Alias NameDefactinibumDefactinibFAKZYNJAPF-4554878VS-6063 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFocal adhesion kinase 1 inhibitors
TargetsFocal adhesion kinase 1
Therapy Area/IndicationsUveal melanomaBrain metastasesSkin Melanoma +[42] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[21] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[6] 
Inactive CompaniesN/A
Active IndicationsBrain metastasesSkin MelanomaSolid tumours +[39] 
Inactive IndicationsUveal melanomaMesotheliomaNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG